Novel risk tool could help prevent strokes in patients with atrial fibrillation

UK patients with the heart rhythm disorder atrial fibrillation could benefit from a new prediction tool for assessing the risk of stroke and major bleeding

An ECG machine read out

New research has found that patients in the UK with the heart rhythm disorder atrial fibrillation could benefit from a novel prediction tool for assessing the risk of stroke and major bleeding.

The study published in the British Journal of General Practice tested the performance of the GARFIELD-AF tool in the UK population using primary care electronic records from more than 460,000 patients. The research project which was funded by the National Institute for Health and Care Research found that the tool had better scores for predicting strokes, major bleeding and death than existing tools used across the UK.

Dr Patricia Apenteng, Research Fellow at the Institute of Applied Health Research at the University of Birmingham and lead author of the paper said:

“Patients with atrial fibrillation have a five-fold increased risk of having a stroke, so effective management of the condition includes a good understanding of all levels of risk. Our findings attest to the potential of the GARFIELD-AF tool to support the management of atrial fibrillation, and there is a need for validation in routine care”.

The team led by researchers at the University of Birmingham and Warwick University tested the GARFIELD-AF tool that predicts the risk of stroke, bleeding and death in the UK population, and compared them with CHA2DS2VASc and HAS-BLED tools which are currently in use.

Patients with atrial fibrillation experience abnormal heart rhythms and can lead to increased risk of stroke and death. Anticoagulation therapy is often used in patients to reduce these risks, but it carries a risk of bleeding. The clinical management of atrial fibrillation involves assessing the risk of stroke and the risk of bleeding to determine if anticoagulation therapy would be beneficial in reducing the risk of stroke.

Dr Patricia Apenteng said:

“Adjusting the algorithm for use in UK clinical practice would optimise its performance in the UK population, and GARFIELD-AF can be embedded in primary care records to support decision-making around anticoagulation. This will ensure that those who need anticoagulation will receive it, and those who do not are not put at unnecessary risk of bleeding complications. The tool also allows the identification of patients with atrial fibrillation who are at risk of early mortality, enabling the initiation of integrated care to improve outcomes.”

Full citation:

Patricia N Apenteng, David Prieto-Merino, Siew Wan Hee, Trudie CA Lobban, Rishi Caleyachetty and David A Fitzmaurice. British Journal of General Practice 16 October 2023; BJGP.2023.0082. DOI: 10.3399/BJGP.2023.0082

Notes for editors

  • For media enquiries please contact Tim Mayo, Press Office, University of Birmingham, tel: +44 (0)7920 405040
  • The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 6,500 international students from over 150 countries.
  • The University of Birmingham is a founding member of Birmingham Health Partners (BHP), a strategic alliance which transcends organisational boundaries to rapidly translate healthcare research findings into new diagnostics, drugs and devices for patients. Birmingham Health Partners is a strategic alliance between seven organisations who collaborate to bring healthcare innovations through to clinical application:
    • University of Birmingham
    • University Hospitals Birmingham NHS Foundation Trust
    • Birmingham Women's and Children's Hospitals NHS Foundation Trust
    • Aston University
    • The Royal Orthopaedic Hospital NHS Foundation Trust
    • Sandwell and West Birmingham Hospitals NHS Trust
    • West Midlands Academic Health Science Network
    • Birmingham and Solihull Mental Health NHS Foundation Trust
  • About the National Institute for Health and Care Research

    The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:

    • Funding high quality, timely research that benefits the NHS, public health and social care;
    • Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
    • Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
    • Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
    • Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
    • Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.

    NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.